PAA

2.63%

19.5¢ pharmaust limited

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-884

First 884 Last

Share
Profile

Follow
enkayess

227 Posts.

126

13/03/24

10:59

Post #: 72861692
Share
Originally posted by Wanderdog: ↑

One other question, and thanks for those that replied, after the trial, which I see may be shortened from the traditional 3 years to less, PAA then produce the final report even if the trial is stopped short from good preliminary results, PAA still have to produce the report to the FDA for fast track approval? This report takes 6 months, then there is a 6 month review period by the FDA. This is still an additional year. I am trying to develop a timeline until we are on the shelf.

Our CEO has stated that the trial should start in the 3rd quarter of this year. This is a Phase 2 study, as that is what comes after the Phase 1 study, but if it shows promising results which look like it will, then this can be rolled into the Phase 3 study? Can it be called a Phase 2/3 study already, I know our CEO calls it that but I do want to see the FDA call it that from the outset but cannot see where they have at present, until during the Phase 2 study when preliminary results are reported on.

Please don't interpret this wrong as I hold PAA, but timeframes are becoming a little optimistic from my knowledge of this sector but happy to be corrected. Timeframes are as below:

Submission of methodology proposal for Phase 2 trail, PAA state from 6-9 months time this will be delivered to FDA.
FDA acceptance of methodology of trial - 3 months
Phase 2 averages 6 months to 2 years, plus FDA review period of 6 months.
Phase 3 averages 2 to 3 years, plus submission of data 6 months, plus FDA review period of 6 months.

time to on the shelf - June 2026 best case, standard case scenario June 2029

Expand

Not sure if you have seen this, may assist:
PAA Price at posting: 35.5¢ Sentiment: Buy Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

There are more pages in this discussion • 541 more messages in this thread...

First 884 Last

Add PAA (ASX) to my watchlist

(20min delay)
Last 19.5¢		Change 0.005(2.63%)		Mkt cap ! $94.89M

Open	High	Low	Value	Volume
19.0¢	19.5¢	19.0¢	$58.40K	305.6K

Buyers (Bids)

No.	Vol.	Price($)
2	115000	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
19.5¢	86074	3

View Market Depth

No.	Vol.	Price($)
1	100000	0.190
8	156232	0.185
10	635662	0.180
10	482365	0.175
8	151233	0.170

Price($)	Vol.	No.
0.195	86074	3
0.200	256824	3
0.205	113150	5
0.210	333355	8
0.215	266995	7

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PAA (ASX) Chart

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-884

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-884

Top Stories

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News